{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:00:34Z","timestamp":1781305234873,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1038\/ncprheum0298","type":"journal-article","created":{"date-parts":[[2006,10,3]],"date-time":"2006-10-03T10:28:46Z","timestamp":1159871326000},"page":"562-569","source":"Crossref","is-referenced-by-count":65,"title":["Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus"],"prefix":"10.1038","volume":"2","author":[{"given":"Nancy E","family":"Lane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncprheum0298_CR1","first-page":"46","volume-title":"Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism","author":"GR Mundy","year":"2003","unstructured":"Mundy GR  et al. (2003) Bone remodeling. In Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism 46\u201357 edn 5 (Ed Favus M). Washington DC: American Society for Bone and Mineral Research"},{"key":"BFncprheum0298_CR2","first-page":"307","volume-title":"Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism","author":"C Cooper","year":"2003","unstructured":"Cooper C (2003) Epidemiology of osteoporosis. In Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism 307\u2013313 edn 5 (Ed Favus M). Washington DC: American Society for Bone and Mineral Research"},{"key":"BFncprheum0298_CR3","first-page":"1922","volume":"24","author":"Y Kipen","year":"1997","unstructured":"Kipen Y  et al. (1997) Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids. J Rheumatol 24: 1922\u20131929","journal-title":"J Rheumatol"},{"key":"BFncprheum0298_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S1297-319X(02)00009-X","volume":"70","author":"IB Coimbra","year":"2003","unstructured":"Coimbra IB and Costallat LT (2003) Bone mineral density in systemic lupus erythematosus and its relation to age at disease onset, plasma estradiol and immunosuppressive therapy. Joint Bone Spine 70: 20\u201323","journal-title":"Joint Bone Spine"},{"key":"BFncprheum0298_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1191\/0961203305lu2039oa","volume":"14","author":"CC Mok","year":"2005","unstructured":"Mok CC  et al. (2005) Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14: 106\u2013112","journal-title":"Lupus"},{"key":"BFncprheum0298_CR6","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1002\/art.21110","volume":"54","author":"IEM Bultink","year":"2005","unstructured":"Bultink IEM  et al. (2005) Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 54: 2044\u20132050","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0298_CR7","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C","volume":"42","author":"R Ramsey-Goldman","year":"1999","unstructured":"Ramsey-Goldman R  et al. (1999) Frequency of fractures in women with systemic lupus erythematosus. Arthritis Rheum 42: 882\u2013890","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0298_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/ard.2003.018127","volume":"64","author":"C-S Yee","year":"2005","unstructured":"Yee C-S  et al. (2005) Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 64: 111\u2013113","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0298_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s11926-005-0056-1","volume":"7","author":"C Lee","year":"2005","unstructured":"Lee C and Ramsey-Goldman R (2005) Bone health and systemic lupus erythematosus. Curr Rheumatol Rep 7: 482\u2013489","journal-title":"Curr Rheumatol Rep"},{"key":"BFncprheum0298_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Van Staa","year":"2003","unstructured":"Van Staa TP  et al. (2003) Bone density threshold and other predictors of vertebral fractures in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48: 224\u2013229","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0298_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8","volume":"39","author":"H Koyama","year":"1997","unstructured":"Koyama H  et al. (1997) Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39: 1403\u20131409","journal-title":"Cancer"},{"key":"BFncprheum0298_CR12","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/cncr.21381","volume":"104","author":"H Lee","year":"2005","unstructured":"Lee H  et al. (2005) Changes in bone mineral density and body composition during initial and long term gonadotropin releasing hormone agonist treatment for prostate carcinoma. Cancer 104: 1633\u20131637","journal-title":"Cancer"},{"issue":"Suppl","key":"BFncprheum0298_CR13","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1007\/s002239900379","volume":"61","author":"M Gambacciani","year":"1997","unstructured":"Gambacciani M  et al. (1997) Ipriflavone prevents loss of bone mass in pharmacological menopause induced by GnRH-agonists. Calcif Tissue Int 61 (Suppl): S15\u2013S18","journal-title":"Calcif Tissue Int"},{"key":"BFncprheum0298_CR14","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1002\/art.11264","volume":"48","author":"E Svenungsson","year":"2003","unstructured":"Svenungsson E  et al. (2003) Elevated triglycerides and low levels of high-density lipoproteins as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha\/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48: 2533\u20132540","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0298_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1365-2796.2005.01502.x","volume":"257","author":"J Frostegard","year":"2005","unstructured":"Frostegard J (2005) SLE, atherosclerosis and cardiovascular disease. J Intern Med 257: 485\u2013495","journal-title":"J Intern Med"},{"key":"BFncprheum0298_CR16","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1161\/01.ATV.0000174800.78362.ec","volume":"25","author":"J Frostegard","year":"2005","unstructured":"Frostegard J (2005) Atherosclerosis in patients with autoimmune disorders. Arterioscler Thomb 25: 1776\u20131785","journal-title":"Arterioscler Thomb"},{"key":"BFncprheum0298_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1161\/01.ATV.12.4.461","volume":"12","author":"J Frostegard","year":"1992","unstructured":"Frostegard J  et al. (1992) Induction of T cell activation by oxidized low density lipoprotein. Arterioscler Thromb 12: 461\u2013467","journal-title":"Arterioscler Thromb"},{"key":"BFncprheum0298_CR18","first-page":"303","volume":"24","author":"C Gabay","year":"1997","unstructured":"Gabay C  et al. (1997) Circulating levels of tumor necrosis factor soluble receptors in SLE are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24: 303\u2013308","journal-title":"J Rheumatol"},{"key":"BFncprheum0298_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/rheumatology\/35.11.1067","volume":"35","author":"A Studnicka-Benke","year":"1996","unstructured":"Studnicka-Benke A  et al. (1996) Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 35: 1067\u20131074","journal-title":"Br J Rheumatol"},{"key":"BFncprheum0298_CR20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1191\/0961203303lu412oa","volume":"12","author":"E Svenungsson","year":"2003","unstructured":"Svenungsson E (2003) TNF alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 12: 454\u2013461","journal-title":"Lupus"},{"key":"BFncprheum0298_CR21","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/1529-0131(200010)43:10<2143::AID-ANR1>3.0.CO;2-S","volume":"43","author":"EM Gravallese","year":"2000","unstructured":"Gravallese EM and Goldring SR (2000) Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 43: 2143\u20132151","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0298_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/ar67","volume":"2","author":"SR Goldring","year":"2000","unstructured":"Goldring SR and Gravellese EM (2000) Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res 2: 33\u201337","journal-title":"Arthritis Res"},{"key":"BFncprheum0298_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/art.20780","volume":"52","author":"J Frostegard","year":"2005","unstructured":"Frostegard J (2005) Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 52: 192\u2013200","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0298_CR24","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/35046102","volume":"408","author":"H Takayanagi","year":"2000","unstructured":"Takayanagi H  et al. (2000) T cell mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-gamma. Nature 408: 600\u2013605","journal-title":"Nature"},{"key":"BFncprheum0298_CR25","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#","volume":"44","author":"S Kotake","year":"2001","unstructured":"Kotake S  et al. (2001) Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44: 1003\u20131012","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0298_CR26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/46303","volume":"402","author":"YY Kong","year":"1999","unstructured":"Kong YY  et al. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304\u2013209","journal-title":"Nature"},{"key":"BFncprheum0298_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.11487","volume":"50","author":"J Zwerina","year":"2004","unstructured":"Zwerina J  et al. (2004) Single and combined inhibitions of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor induced arthritis: effects of synovial inflammation, bone erosion and cartilage destruction. Arthritis Rheum 50: 277\u2013290","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0298_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2003.10.005","volume":"15","author":"S Kwan Tat","year":"2004","unstructured":"Kwan Tat S  et al. (2004) IL-6, RANKL, TNF-alpha\/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15: 49\u201360","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFncprheum0298_CR29","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1073\/pnas.92.9.3893","volume":"92","author":"S Stemme","year":"1995","unstructured":"Stemme S  et al. (1995) T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoproteins. Proc Natl Acad Sci USA 92: 3893\u20133897","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncprheum0298_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1474-9728.2004.00127.x","volume":"3","author":"EJ Moerman","year":"2004","unstructured":"Moerman EJ  et al. (2004) Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma\/stem cells: the role of PPAR-\u03b32 transcription factor and TGF-\u03b2\/BMD signaling pathways. Aging Cell 3: 379\u2013389","journal-title":"Aging Cell"},{"key":"BFncprheum0298_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-4933-2-14","volume":"2","author":"L Ginaldi","year":"2005","unstructured":"Ginaldi L  et al. (2005) Osteoporosis, inflammation and aging. Immun Ageing 2: 14\u201318","journal-title":"Immun Ageing"},{"key":"BFncprheum0298_CR32","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1073\/pnas.94.9.4318","volume":"94","author":"SA Kliewer","year":"1998","unstructured":"Kliewer SA  et al. (1998) Fatty acids and icosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma. Proc Natl Acad Sci USA 94: 4318\u20134323","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncprheum0298_CR33","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1074\/jbc.M100878200","volume":"276","author":"SS Davies","year":"2001","unstructured":"Davies SS  et al. (2001) Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J Biol Chem 276: 16015\u201316023","journal-title":"J Biol Chem"},{"key":"BFncprheum0298_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1359\/jbmr.2001.16.1.182","volume":"16","author":"F Parhami","year":"2001","unstructured":"Parhami F  et al. (2001) Atherogenic high-fat diet reduces bone mineralization in mice. J Bone Miner Res 16: 182\u2013188","journal-title":"J Bone Miner Res"},{"key":"BFncprheum0298_CR35","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMoa032739","volume":"350","author":"RR McLean","year":"2004","unstructured":"McLean RR  et al. (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350: 2042\u20132049","journal-title":"N Engl J Med"},{"key":"BFncprheum0298_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00296-004-0466-9","volume":"25","author":"Z Yesilova","year":"2005","unstructured":"Yesilova Z  et al. (2005) Hyperhomocysteinemia in patients with Behcet's disease: is it due to inflammation or therapy? Rheumatol Int 25: 423\u2013428","journal-title":"Rheumatol Int"},{"key":"BFncprheum0298_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0889-857X(05)70196-4","volume":"27","author":"NE Lane","year":"2001","unstructured":"Lane NE (2001) An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 27: 235\u2013254","journal-title":"Rheum Dis Clin North Am"},{"key":"BFncprheum0298_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0889-857X(05)70140-X","volume":"26","author":"G Cunnane","year":"2000","unstructured":"Cunnane G and Lane NE (2000) Steroid-induced osteoporosis in systemic lupus erythematosus. Rheum Dis Clin North Am 26: 311\u2013329","journal-title":"Rheum Dis Clin North Am"},{"key":"BFncprheum0298_CR39","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1359\/jbmr.1999.14.7.1061","volume":"14","author":"SC Manolagas","year":"1999","unstructured":"Manolagas SC and Weinstein RS (1999) New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14: 1061\u20131066","journal-title":"J Bone Miner Res"},{"key":"BFncprheum0298_CR40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1172\/JCI2799","volume":"102","author":"RS Weinstein","year":"1998","unstructured":"Weinstein RS  et al. (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest 102: 274\u2013282","journal-title":"J Clin Invest"},{"issue":"Suppl","key":"BFncprheum0298_CR41","first-page":"S14","volume":"1","author":"O Johnell","year":"2002","unstructured":"Johnell O  et al. (2002) Oral corticosteroids increase fracture risk independently of BMD [abstract]. Osteoporosis Int 1 (Suppl): S14","journal-title":"Osteoporosis Int"},{"key":"BFncprheum0298_CR42","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/jbmr.5650040202","volume":"4","author":"D Dempster","year":"1989","unstructured":"Dempster D (1989) Iliac crest biopsy: bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4: 137\u2013141","journal-title":"J Bone Miner Res"},{"key":"BFncprheum0298_CR43","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/art.10277","volume":"46","author":"Q Rehman","year":"2002","unstructured":"Rehman Q  et al. (2002) Quantitative computed tomography of the lumbar spine, not dual X-ray absorptiometry, is an independent predictor of prevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone-replacement therapy. Arthritis Rheum 46: 1292\u20131297","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0298_CR44","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00198-004-1736-9","volume":"16","author":"KC Lian","year":"2005","unstructured":"Lian KC  et al. (2005) Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naive postmenopausal women. Osteoporosis Int 16: 642\u2013650","journal-title":"Osteoporosis Int"},{"key":"BFncprheum0298_CR45","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1359\/JBMR.051103","volume":"21","author":"NE Lane","year":"2006","unstructured":"Lane NE  et al. (2006) A proposed mechanism for increased bone fragility in patients treated with glucocorticoids: enlargement and hypomineralization of bone matrix surrounding osteocyte lacunae. J Bone Miner Res 21: 466\u2013476","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"BFncprheum0298_CR46","first-page":"S067","volume":"20","author":"G Balooch","year":"2005","unstructured":"Balooch G  et al. (2005) Both risedronate and PTH maintain bone mechanical properties and matrix composition in a mouse model of glucocorticoid-induced osteoporosis. J Bone Miner Res 20 (Suppl 1): S067","journal-title":"J Bone Miner Res"},{"key":"BFncprheum0298_CR47","first-page":"1812","volume-title":"Kelley's Textbook of Rheumatology","author":"M Rizzo","year":"2005","unstructured":"Rizzo M and Urbaniak JR (2005) Osteonecrosis. In Kelley's Textbook of Rheumatology, 1812\u20131828 (vol 2) edn 7 (Eds Harris  et al.). Philadelphia: Elsevier, Saunders"},{"key":"BFncprheum0298_CR48","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2106\/00004623-197759060-00003","volume":"59","author":"GJ Wang","year":"1997","unstructured":"Wang GJ  et al. (1997) Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J Bone Joint Surg Am 59: 729\u2013735","journal-title":"J Bone Joint Surg Am"},{"key":"BFncprheum0298_CR49","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.berh.2005.06.005","volume":"19","author":"A Kelman","year":"2005","unstructured":"Kelman A and Lane NE (2005) The management of secondary osteoporosis. Best Pract Res Clin Rheumatol 19: 1021\u20131037","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"BFncprheum0298_CR50","first-page":"336","volume-title":"Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism","author":"N Watts","year":"2003","unstructured":"Watts N (2003) Biophosphates for treatment of osteoporosis. In Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism, 336\u2013341 edn 5 (Ed Favus M). Washington DC: American Society for Bone and Mineral Research"},{"key":"BFncprheum0298_CR51","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM  et al. (2001) Effect of parathyroid hormone1\u201334 on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434\u20131441","journal-title":"N Engl J Med"},{"key":"BFncprheum0298_CR52","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI3914","volume":"102","author":"NE Lane","year":"1998","unstructured":"Lane NE  et al. (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102: 1627\u20131633","journal-title":"J Clin Invest"}],"container-title":["Nature Clinical Practice Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0298","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T21:00:27Z","timestamp":1684443627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncprheum0298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["BFncprheum0298"],"URL":"https:\/\/doi.org\/10.1038\/ncprheum0298","relation":{},"ISSN":["1745-8382","1745-8390"],"issn-type":[{"value":"1745-8382","type":"print"},{"value":"1745-8390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}